bcd-217
mAbexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started Jul 31, 2019 (NCT03913923)
Timeline
Indications
Studied for
Mechanism of action
- Programmed cell death protein 1INHIBITOR
PDCD1 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05751928 | Phase 3 | Apr 5, 2023 | Biocad |
| NCT05732805 | Phase 3 | Aug 2, 2022 | Biocad |
| NCT03913923 | Phase 2 | Jul 31, 2019 | Biocad |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biocad | For profit | 3 | 3 | 2 | 2019 |
1 organizations
Page 1 / 1